Core Viewpoint - The stock of Beijing Baipusi Biotechnology Co., Ltd. has experienced fluctuations, with a year-to-date increase of 90.35% but a recent decline of 8.20% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Baipusi achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26% [2] - The net profit attributable to shareholders for the same period was 132 million yuan, showing a year-on-year increase of 58.61% [2] Shareholder Information - As of September 30, 2025, the number of Baipusi shareholders decreased by 9.75% to 10,600 [2] - The average number of circulating shares per shareholder increased by 54.93% to 11,947 shares [2] Dividend Distribution - Since its A-share listing, Baipusi has distributed a total of 432 million yuan in dividends, with 312 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the second-largest circulating shareholder, holding 13.56 million shares, an increase of 7.57 million shares from the previous period [3] - The top ten circulating shareholders include several funds, with notable increases in holdings from institutions like China Europe Medical Health Mixed A and China Europe Medical Innovation Stock A [3]
百普赛斯跌2.04%，成交额4688.28万元，主力资金净流入12.01万元